Dr. David K K. Imagawa, MD

Dr. Imagawa practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Imagawa's NPI, 1467532630, was assigned on October 16, 2006. Dr. Imagawa graduated from The Johns Hopkins University School of Medicine in 1986. Dr. Imagawa holds California license 000000A44277.

Dr. Imagawa's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Imagawa's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. Dr. Imagawa is also affiliated with Hoag Hospital Newport Beach. The medical group on file is UCI Health Physicians. Dmand AI also links Dr. Imagawa to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Imagawa practices, 4 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Imagawa's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Imagawa is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Imagawa's licenses on file in 2 states: California and Florida.

Dmand AI lists esophagus, stomach, or upper small intestine surgery and gallbladder removal among the conditions Dr. Imagawa treats.

CMS data shows 516 Medicare services from Dr. Imagawa across 11 procedure codes in 2024, for 190 Medicare patients. Medicare paid $39,514 for them.

CMS counts 190 Medicare patients who saw Dr. Imagawa in 2024. The largest group is 65 to 74, with 89 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 35% are also on Medicaid. Their average risk score is 2.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Imagawa's median patient age at 68, with 53% women.

In 2024, Dr. Imagawa wrote 107 Medicare Part D claims for 39 patients. 72% of them were for generic drugs. CMS names the drug for 29 of them, across 2 drugs with 11 or more claims each, at $9,983 in total drug cost. In 2022, CMS named 74 claims across 5 drugs.

Dr. Imagawa accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Imagawa as offering telehealth.

Dmand AI links 49 papers to Dr. Imagawa, published from 2010 to 2025. 2013 was the busiest year, with 3. The most frequent topics are Pancreatectomy, Pancreatic Neoplasms and Pancreaticoduodenectomy. Dr. Imagawa has published most often in Am Surg. Dr. Imagawa's most frequent co-authors are Zeljka Jutric, MD, Areg Grigorian, MD and Matthew Harold Katz, MD.

Dmand AI links Dr. Imagawa to 2 clinical trials. Conditions studied include Carcinoma, Hepatocellular and Liver Neoplasms.

CMS Open Payments shows 218 general payments to Dr. Imagawa from 36 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 46% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $22,494.

Dmand AI lists 32 awards for Dr. Imagawa, most recently America's Most Honored Professionals - Top 1% in 2017.

Dr. Imagawa graduated from The Johns Hopkins University School of Medicine in 1986. Dr. Imagawa is a member of ACS, ASTS, AHPBA, APHPBA, AAS and CRSA.

Dr. Imagawa is in network with 7 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.